RxDoctor Payments Data

Justin Voris, MD

Family Medicine · Fort Smith, ARNPI 1356600829

Payments from drug & device makers

$7,701in general payments, 2019–2025

Across 510 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$771
  • Pfizer$537
  • Lilly USA, LLC$524
  • Amgen$452
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$7,679100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,701 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$63,003
Medicare patients
204
Services billed
1,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$76,576
EliquisApixaban58$44,381
TrulicityDulaglutide41$38,498
MounjaroTirzepatide25$35,722
JardianceEmpagliflozin30$34,977
JanuviaSitagliptin Phosphate24$28,405
XareltoRivaroxaban37$23,098
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$18,237
Soliqua 100-33Insulin Glargine/Lixisenatide21$17,701
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$16,853
Tresiba Flextouch U-200Insulin Degludec19$11,403
FarxigaDapagliflozin Propanediol19$10,193
Tresiba Flextouch U-100Insulin Degludec13$6,621
Breo ElliptaFluticasone/Vilanterol13$5,501
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$771$76,57652 claims
Lilly USA, LLCTrulicity, Mounjaro$524$74,22066 claims
PfizerEliquis, Prempro$537$46,87469 claims
Boehringer IngelheimJardiance$114$34,97730 claims
MerckJanuvia$80$28,40524 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,062$27,04742 claims
GSKTrelegy Ellipta, Breo Ellipta$448$23,73829 claims
Johnson & JohnsonXarelto$229$23,09837 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$93$17,70121 claims
AbbVieSynthroid$1,412$1,07015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →